Literature DB >> 2043916

Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig.

C M Villalón1, M O den Boer, J P Heiligers, P R Saxena.   

Abstract

1. It has recently been shown that the tachycardic response to 5-hydroxytryptamine (5-HT) in the anaesthetized pig, being mimicked by 5-methoxytryptamine and renzapride and blocked by high doses of ICS 205-930, is mediated by the putative 5-HT4 receptor. In the present investigation we have further characterized this receptor. 2. Intravenous bolus injections of the tryptamine derivatives, 5-HT (3, 10 and 30 micrograms kg-1), 5-methoxytryptamine (3, 10 and 30 micrograms kg-1) and alpha-methyl-5-hydroxytryptamine (alpha-methyl-5-HT; 3, 10, 30 and 100 micrograms kg-1), resulted in dose-dependent increases in heart rate of, respectively, 25 +/- 2, 48 +/- 3 and 68 +/- 3 beats min-1 (5-HT; n = 35); 15 +/- 1, 32 +/- 2 and 57 +/- 3 beats min-1 (5-methoxytryptamine; n = 30); 6 +/- 4, 18 +/- 6, 34 +/- 6 and 64 +/- 11 beats min-1 (alpha-methyl-5-HT; n = 3). 3. The increases in heart rate following i.v. administration of certain substituted benzamide derivatives were genereally less marked and not dose-dependent: 1 + 5, 11 + 3 and 10 + 5 beats min1- after 300, 1000 and 3000,jgkg' of metoclopramide, respectively, (n = 8); 21 + 4, 19 + 2 and 2 + 2 beats min'- after 100, 300 and lOOOIpgkg1- of cisapride, respectively, (n = 5); 6 + 2, 14 + 2, 37 + 6, 43 + 8 and 34 + 10 beats min- after 10, 30, 100, 300 and lOOOjigkg' of zacopride, respectively, (n = 6); and 1 + 1, 2 + 1 and 5 + 2 beats min- 1 after 300, 1000 and 3000 pg kg' of dazopride, respectively, (n = 4). These drugs behaved as partial agonists, antagonizing the responses to 5-HT and 5-methoxytryptamine dosedependently. 4. The 5-HT3 receptor agonist 1-phenyl-biguanide (100, 300 and lOOOpgkg-1) induced only slight increases in heart rate of 1 + 1, 6 + 2 and 11 + 1 beats min 1, respectively, (n = 3). These effects were not antagonized by the selective 5-HT3 receptor antagonist granisetron (3mgkg-1). In addition, 1-phenylbiguanide (1000,pg kg- 1) did not modify the tachycardia induced by either 5-HT- or 5- methoxytryptamine. 5. High doses (3mg kg- 1) of ICS 205-930, a 5-HT3 receptor antagonist with an indole group and devoid of effects on porcine heart rate per se, antagonized the stimulatory effects of 5-HT, 5-methoxytryptamine, alpha-Me-5-HT, metoclopramide, cisapride, zacopride, dazopride and 1-phenyl-biguanide. However, the 5-HT2 receptor antagonist ketanserin (0.5 mg kg- 1), the 5-HT3 receptor antagonists granisetron (3mg kg- 1) and MDL 72222 (3mg kg- ') and the dopamine D2 receptor antagonist domperidone (3 mg kg- 1) had no antagonist activity. 6. The above results support our contention that 5-HT, 5-methoxytryptamine, alpha-Me-5-HT and the substituted benzamide derivatives increase porcine heart rate by a direct action on the cardiac pacemaker, via the activation of a putative 5-HT4 receptor. The pharmacological profile of this novel 5-HT receptor is similar (neurones from mouse brain colliculi and human heart) or, perhaps, even identical (guinea-pig cholinergic neurones) to other putative 5-HT4 receptors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2043916      PMCID: PMC1917868          DOI: 10.1111/j.1476-5381.1991.tb12140.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

Review 1.  Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction.

Authors:  M D Tricklebank
Journal:  Trends Pharmacol Sci       Date:  1989-04       Impact factor: 14.819

2.  Pharmacological characterization of a neuronal receptor for 5-hydroxytryptamine in guinea pig ileum with properties similar to the 5-hydroxytryptamine receptor.

Authors:  D A Craig; D E Clarke
Journal:  J Pharmacol Exp Ther       Date:  1990-03       Impact factor: 4.030

Review 3.  The 5-HT4 receptor: naughty, but nice.

Authors:  D E Clarke; D A Craig; J R Fozard
Journal:  Trends Pharmacol Sci       Date:  1989-10       Impact factor: 14.819

4.  Mediation of 5-hydroxytryptamine-induced tachycardia in the pig by the putative 5-HT4 receptor.

Authors:  C M Villalón; M O den Boer; J P Heiligers; P R Saxena
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

5.  A 5-hydroxytryptamine receptor in human atrium.

Authors:  A J Kaumann; L Sanders; A M Brown; K J Murray; M J Brown
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

Review 6.  Cardiovascular effects of serotonin agonists and antagonists.

Authors:  P R Saxena; C M Villalón
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

7.  Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron).

Authors:  G J Sanger; D R Nelson
Journal:  Eur J Pharmacol       Date:  1989-01-10       Impact factor: 4.432

8.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Authors:  J M Van Nueten; P A Janssen; J Van Beek; R Xhonneux; T J Verbeuren; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

9.  Selective DA2 versus DA1 antagonist activity of domperidone in the periphery.

Authors:  J D Kohli; D Glock; L I Goldberg
Journal:  Eur J Pharmacol       Date:  1983-04-22       Impact factor: 4.432

10.  MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors.

Authors:  J R Fozard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-05       Impact factor: 3.000

View more
  19 in total

1.  Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors.

Authors:  Araceli Sánchez-Lopez; David Centurión; Erika Vázquez; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

2.  Fading of 5-HT4 receptor-mediated inotropic responses to 5-hydroxytryptamine is caused by phosphodiesterase activity in porcine atrium.

Authors:  Alberto J Kaumann; Finn Olav Levy
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

3.  Labelling with [125I]-SB 207710 of a small 5-HT4 receptor population in piglet right atrium: functional relevance.

Authors:  A J Kaumann; J A Lynham; A M Brown
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

4.  Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development.

Authors:  Joris H De Maeyer; Roel Straetemans; Jan A J Schuurkes; Romain A Lefebvre
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

5.  Characterization of the 5-HT4 receptor mediating tachycardia in piglet isolated right atrium.

Authors:  A D Medhurst; A J Kaumann
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

6.  A 5-HT4-like receptor in human right atrium.

Authors:  A J Kaumann; L Sanders; A M Brown; K J Murray; M J Brown
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-08       Impact factor: 3.000

Review 7.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

Authors:  Carlos M Villalón; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-17       Impact factor: 3.000

8.  5-Hydroxytryptamine increases contractile force in porcine right atrium but not in left ventricle.

Authors:  R G Schoemaker; X Y Du; W A Bax; P R Saxena
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-11       Impact factor: 3.000

9.  Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors.

Authors:  C A Rizzi; A Sagrada; A Schiavone; P Schiantarelli; R Cesana; G B Schiavi; H Ladinsky; A Donetti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-04       Impact factor: 3.000

10.  Characterization of a novel 5-HT4 receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285.

Authors:  A Dumuis; H Gozlan; M Sebben; H Ansanay; C A Rizzi; M Turconi; E Monferini; E Giraldo; P Schiantarelli; H Ladinsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.